Statement of Changes in Beneficial Ownership (4)
March 12 2021 - 4:36PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
TOBIN JAMES R |
2. Issuer Name and Ticker or Trading Symbol
Oxford Immunotec Global PLC
[
OXFD
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
|
|
(Last)
(First)
(Middle)
C/O OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE |
3. Date of Earliest Transaction
(MM/DD/YYYY)
3/8/2021 |
|
(Street)
ABINGDON, OXFORDSHIRE, X0 OX14 4RZ
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
| Ordinary Shares | 3/8/2021 | | D | | 4081 | D | $22 (1) | 0 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code
(Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) | 8. Price of Derivative Security
(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Option (Right to Buy) | $8.65 | 3/8/2021 | | D | | | 7457 | (2) | 6/28/2026 | Ordinary Shares | 7457 | $13.35 (3) | 0 | D | |
| Stock Option (Right to Buy) | $14.46 | 3/8/2021 | | D | | | 7457 | (2) | 6/6/2027 | Ordinary Shares | 7457 | $7.54 (3) | 0 | D | |
| Stock Option (Right to Buy) | $14.49 | 3/8/2021 | | D | | | 7457 | (2) | 6/19/2028 | Ordinary Shares | 7457 | $7.51 (3) | 0 | D | |
| Stock Option (Right to Buy) | $14.44 | 3/8/2021 | | D | | | 7457 | (2) | 6/18/2029 | Ordinary Shares | 7457 | $7.56 (3) | 0 | D | |
| Stock Option (Right to Buy) | $13.02 | 3/8/2021 | | D | | | 14914 | (2) | 12/1/2024 | Ordinary Shares | 14914 | $8.98 (3) | 0 | D | |
| Stock Option (Right to Buy) | $13.02 | 3/8/2021 | | D | | | 7457 | (2) | 12/1/2024 | Ordinary Shares | 7457 | $8.98 (3) | 0 | D | |
| Stock Option (Right to Buy) | $14.17 | 3/8/2021 | | D | | | 7457 | (2) | 6/9/2025 | Ordinary Shares | 7457 | $7.83 (3) | 0 | D | |
| Stock Option (Right to Buy) | $12.96 | 3/8/2021 | | D | | | 9494 | (2) | 6/24/2030 | Ordinary Shares | 9494 | $9.04 (3) | 0 | D | |
| Explanation of Responses: |
| (1) | Disposed pursuant to the acquisition by PerkinElmer (UK) Holdings Limited of the entire issued share capital of Oxford Immunotec Global PLC on March 8, 2021 by means of a scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme"). |
| (2) | In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| (3) | Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
TOBIN JAMES R
C/O OXFORD IMMUNOTEC GLOBAL PLC
94C INNOVATION DRIVE
ABINGDON, OXFORDSHIRE, X0 OX14 4RZ | X |
|
|
|
Signatures
|
| /s/ Matthew T E McLaughlin, as Attorney-in-Fact for James R. Tobin | | 3/12/2021 |
| **Signature of Reporting Person | Date |
Oxford Immunotec Global (NASDAQ:OXFD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Immunotec Global (NASDAQ:OXFD)
Historical Stock Chart
From May 2023 to May 2024
